Editorial Response: U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis
Open Access
- 1 January 1999
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 28 (1) , 49-51
- https://doi.org/10.1086/515086
Abstract
Jonathan D. Berman; Editorial Response: U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral LeishmaniasThis publication has 0 references indexed in Scilit: